JP2012515165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515165A5 JP2012515165A5 JP2011545498A JP2011545498A JP2012515165A5 JP 2012515165 A5 JP2012515165 A5 JP 2012515165A5 JP 2011545498 A JP2011545498 A JP 2011545498A JP 2011545498 A JP2011545498 A JP 2011545498A JP 2012515165 A5 JP2012515165 A5 JP 2012515165A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- mammalian
- ranges
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 2
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14413409P | 2009-01-12 | 2009-01-12 | |
| US61/144,134 | 2009-01-12 | ||
| PCT/US2010/020673 WO2010081112A1 (en) | 2009-01-12 | 2010-01-11 | Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012515165A JP2012515165A (ja) | 2012-07-05 |
| JP2012515165A5 true JP2012515165A5 (enExample) | 2013-02-28 |
| JP5981141B2 JP5981141B2 (ja) | 2016-08-31 |
Family
ID=42316862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011545498A Active JP5981141B2 (ja) | 2009-01-12 | 2010-01-11 | 多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8956605B2 (enExample) |
| EP (1) | EP2385841B1 (enExample) |
| JP (1) | JP5981141B2 (enExample) |
| CN (1) | CN102348463B (enExample) |
| AU (1) | AU2010203446B2 (enExample) |
| CA (1) | CA2748392C (enExample) |
| WO (1) | WO2010081112A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| EA035645B1 (ru) | 2013-03-15 | 2020-07-21 | Дженентек, Инк. | ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| EP3442562B1 (en) | 2016-04-15 | 2022-09-21 | Evive Biotechnology (Shanghai) Ltd | An il-22 dimer for use in treating necrotizing enterocolitis |
| CN112007146A (zh) * | 2020-09-03 | 2020-12-01 | 上海市儿童医院 | Il-22在治疗和/或预防脓毒症诱发的肝脏损伤的药物中的用途 |
| US20240033232A1 (en) * | 2021-03-10 | 2024-02-01 | Wen Tan | New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030003545A1 (en) | 1998-05-29 | 2003-01-02 | Reinhard Ebner | Interleukins-21 and 22 |
| US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| US7226591B2 (en) * | 2000-05-22 | 2007-06-05 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
| CN101219208B (zh) * | 2005-01-04 | 2010-08-11 | 健能隆医药技术（上海）有限公司 | 白介素-22的医药用途 |
| CN100515491C (zh) * | 2005-01-04 | 2009-07-22 | 健能隆医药技术（上海）有限公司 | 白介素-22的医药用途 |
| AU2007261019A1 (en) * | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating IL-22 and IL-17 |
| WO2008085229A2 (en) * | 2006-11-15 | 2008-07-17 | Arteriocyte Inc. | Cell-based therapies for treating liver disease |
| CN101168049A (zh) * | 2007-10-23 | 2008-04-30 | 中国人民解放军军事医学科学院基础医学研究所 | 白介素-22在制备治疗肝病药物中的应用及其制备方法 |
-
2010
- 2010-01-11 AU AU2010203446A patent/AU2010203446B2/en not_active Ceased
- 2010-01-11 US US13/142,423 patent/US8956605B2/en active Active
- 2010-01-11 WO PCT/US2010/020673 patent/WO2010081112A1/en not_active Ceased
- 2010-01-11 EP EP10729641.0A patent/EP2385841B1/en active Active
- 2010-01-11 CN CN201080010768.7A patent/CN102348463B/zh active Active
- 2010-01-11 JP JP2011545498A patent/JP5981141B2/ja active Active
- 2010-01-11 CA CA2748392A patent/CA2748392C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515165A5 (enExample) | ||
| Li et al. | Role of interleukin-17 in acute pancreatitis | |
| Gao et al. | The potential role of IL-33/ST2 signaling in fibrotic diseases | |
| JP2018109052A5 (enExample) | ||
| NO20082434L (no) | Materialer og fremgangsmater for behandling av kroniske fibrotiske sykdommer | |
| CL2007003690A1 (es) | Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas. | |
| JP2007262090A5 (enExample) | ||
| JP2011511805A5 (enExample) | ||
| JP2011528896A5 (enExample) | ||
| JP2013503110A5 (enExample) | ||
| WO2010107177A2 (ko) | 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물 | |
| UY27965A1 (es) | Derivados heterocíclicos | |
| JP2017141225A5 (enExample) | ||
| JP2007532685A5 (enExample) | ||
| NZ601592A (en) | Recombinant elastase proteins and methods of manufacturing and use thereof | |
| WO2011115456A3 (ko) | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 | |
| AU2012334804A8 (en) | Modulators of C3a receptors | |
| NO20092024L (no) | En farmasoytisk sammensetning med antipsykotisk, antidepressiv eller antiepileptisk aktivitet med redusert bivirkning | |
| JP2020502134A5 (enExample) | ||
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
| Hansdottir et al. | Smoking disrupts vitamin D metabolism in the lungs | |
| Feola et al. | Macrophage Phenotype Is Controlled by Inhibition of the NF-κB Signaling Pathway. | |
| Jimenez et al. | Response to comments on" Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects" by José L. Jiménez, Viktoriya Stalbovskaya and Byron Jones, Pharmaceutical Statistics, 2019; 18: 287-303 | |
| Watanabe et al. | Regulation of GROα production in human bronchial epithelial cells | |
| Yanagisawa et al. | Effects of Pulmonary Exposure to Carbon Nanotubes on Lung and Systemic Inflammation with Coagulopathy Induced by Lipopolysaccharide in Mice. |